BofA update shows where active managers are putting money
HOUSTON - Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage biotech company with a market capitalization of $16.3 million, reported Tuesday that its Phase 1 APOLLO study of MT-601 therapy demonstrated a 66% objective response rate in patients with Non-Hodgkin Lymphoma (NHL), with 50% achieving complete response. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet.
The clinical trial investigated MT-601, a Multi-Antigen Recognizing T cell product, in 24 patients with B-cell lymphoma across seven U.S. clinical sites. Patients had received a median of five prior lines of therapy, including CAR-T cell treatments and bispecific antibodies. While the company’s gross profit margin stands at -194.5%, typical for a development-stage biotech company, its current ratio of 3.45 indicates strong short-term financial stability.
According to the company’s press release statement, the therapy showed a favorable safety profile with no dose limiting toxicities or immune-effector cell associated neurotoxicity syndrome in the dose escalation cohort. Only two cases of Grade 1 cytokine release syndrome were reported, which required no treatment.
The study also reported durable responses ranging from 3 to 24 months, with five NHL patients showing continued response for six months or longer, including three patients with responses lasting 12 months or more.
In Hodgkin Lymphoma patients, who had undergone a median of eight prior lines of therapy, seven out of nine patients (78%) achieved objective responses, with one patient demonstrating complete response.
The Safety Review Committee has cleared the pre-specified maximum dose of 400 million cells for the dose expansion phase of the trial, which will focus on patients with Diffuse Large B Cell Lymphoma who have relapsed after CAR-T therapy or are ineligible for it.
MT-601 is designed to target six different tumor antigens upregulated in lymphoma cells. Unlike CAR-T cell therapies, MT-601 is not genetically modified, which the company suggests may make it easier and less expensive to manufacture.
The APOLLO study is supported by the National Cancer Institute of the National Institutes of Health. Marker Therapeutics plans to provide another data update in the first half of 2026. With analysts maintaining a Strong Buy consensus and setting price targets significantly above the current trading price of $1.26, InvestingPro subscribers can access additional insights, including 8 more ProTips and detailed financial metrics to better evaluate the company’s potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.